Physician profile
Robert C Waldrop
NPI 1043372444
$19,778.42
in general payments reported to CMS, 2019-2025
70 companies · $3,081 in 2025
The $3,081 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,894 · 2020: $1,854 · 2021: $2,899 · 2022: $2,473 · 2023: $3,026 · 2024: $3,552 · 2025: $3,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,569 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,569.25 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,036.59 | 2019-2025 | Botox, Duopa, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,264.70 | 2019-2025 | |
| Biogen, INC. | $977.65 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $974.32 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $880.42 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $843.16 | 2019-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $675.78 | 2019-2025 | Nuplazid |
| Upsher-Smith Laboratories LLC | $663.95 | 2019-2022 | |
| Lundbeck LLC | $638.08 | 2020-2025 | Vyepti |
| Amgen INC. | $605.47 | 2019-2023 | Aimovig |
| Eisai INC. | $544.35 | 2019-2025 | |
| Allergan, INC. | $530.05 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $512.58 | 2019-2025 | Rytary, Crexont, Ongentys |
| Lilly USA, LLC | $501.35 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $499.03 | 2019-2025 | Austedo Xr, Austedo Xr |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Waldrop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.